WASHINGTON, DC, United States (AFP) - A US Government-convened expert committee on Friday voted against recommending the approval of the first new Alzheimer's drug in almost two decades, after finding insufficient evidence of its benefit. The decisions reached by such panels, while non-binding, are often accepted by the Food and Drug Administration (FDA).
